Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis

Basit Öğe Kaydı
dc.contributor.authorSarici, Ahmet
dc.contributor.authorTanriverdi, Lokman H.
dc.contributor.authorHernandez, Adrian, V
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorSaglio, Giuseppe
dc.date.accessioned2026-04-04T13:33:13Z
dc.date.available2026-04-04T13:33:13Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description67th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 06-09, 2025 -- Orlando, FL
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Hematol
dc.identifier.doi10.1182/blood-2025-7298
dc.identifier.endpage7298
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.startpage7298
dc.identifier.urihttps://doi.org/10.1182/blood-2025-7298
dc.identifier.urihttps://hdl.handle.net/11616/108990
dc.identifier.volume146
dc.identifier.wosWOS:001669688500048
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofBlood
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectChronic myeloid leukemia
dc.subjectAsciminib
dc.subjectTyrosine kinase inhibitors
dc.subjectMajor molecular response
dc.subjectgrade >3 adverse events
dc.titleAsciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu